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ABSTRACT: Multidrug resistance proteins that belong to the
ATP-binding cassette family like the human P-glycoprotein
(ABCB1 or Pgp) are responsible for many failed cancer and
antiviral chemotherapies because these membrane transporters
remove the chemotherapeutics from the targeted cells.
Understanding the details of the catalytic mechanism of Pgp
is therefore critical to the development of inhibitors that might
overcome these resistances. In this work, targeted molecular
dynamics techniques were used to elucidate catalytically
relevant structures of Pgp. Crystal structures of homologues
in four diﬀerent conformations were used as intermediate targets in the dynamics simulations. Transitions from conformations
that were wide open to the cytoplasm to transition state conformations that were wide open to the extracellular space were
studied. Twenty-six nonredundant transitional protein structures were identiﬁed from these targeted molecular dynamics
simulations using evolutionary structure analyses. Coupled movement of nucleotide binding domains (NBDs) and
transmembrane domains (TMDs) that form the drug binding cavities were observed. Pronounced twisting of the NBDs as
they approached each other as well as the quantiﬁcation of a dramatic opening of the TMDs to the extracellular space as the ATP
hydrolysis transition state was reached were observed. Docking interactions of 21 known transport ligands or inhibitors were
analyzed with each of the 26 transitional structures. Many of the docking results obtained here were validated by previously
published biochemical determinations. As the ATP hydrolysis transition state was approached, drug docking in the extracellular
half of the transmembrane domains seemed to be destabilized as transport ligand exit gates opened to the extracellular space.
A
BC transporters constitute a family of proteins that
conduct important cellular transport functions. Some
members of this family catalyze the import of nutrients, while
others are responsible for the export of wastes and toxins,
especially amphipathic or hydrophobic cytotoxins.
1,2 Several
members of this family also cause problems in the treatment of
cancer and viral infections because of their role in exporting
cytotoxic chemotherapeutics administered for the treatment of
cancer or viral infection.
3−5 One of these problematic
transporters is the multidrug resistance P-glycoprotein (Pgp
or ABCB1). Pgp is a 1280-residue, single polypeptide that
contains two transmembrane domains (TMDs) and two
nucleotide binding domains (NBDs) with a TMD1−NBD1−
TMD2−NBD2 topology. The two nucleotide binding sites are
shared between the large N- and C-terminal nucleotide binding
domains. Each TMD consists of six transmembrane helices
responsible for the binding and discharge of transported
substrates. The binding sites for transport substrates [drug
binding sites (DBS)] are formed by interaction of several
transmembrane helices.
6−11 Some sites appear to be large
enough to accommodate more than one drug molecule at a
time.
12 ATP hydrolysis is stimulated in the presence of drugs
that are transported, indicating direct coupling of drug
transport and ATP hydrolysis.
13−15 ATP hydrolysis most likely
occurs via an alternating site mechanism.
16 Formation and
collapse of the catalytic transition state may be directly coupled
to the transport of drug across the membrane.
13
Although high-resolution structures of the human Pgp are
not yet available, crystal structures for mouse Pgp
17 and several
bacterial homologues exist.
18−20 In the structural model for
mouse Pgp, the catalytic glutamates that likely activate the
waters used in hydrolysis of ATP
21 are separated by >30 Å,
indicative of a complete disengagement of the two NBDs. Very
similar structures resulted when the mouse Pgp was cocrystal-
lized with two diﬀerent stereoisomers of cyclic tris-valinesele-
nazole inhibitors bound in the DBS.
17 The widely opened
NBDs in these structures create a 9 Å opening for access to the
DBS on the cytoplasmic side of the membrane that are formed
by transmembrane (TM) helices (TM4 with TM6 and TM10
with TM12).
17 Structures of the closely related Staphylococcus
aureus multidrug transporter (SAV1866) have been obtained
with either ADP bound or the nonhydrolyzable AMP-PNP
bound to the nucleotide binding sites.
18,19 SAV1866 was shown
to transport many compounds that are known transport
substrates for human Pgp.
22 The crystal structures of SAV1866
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residues separated by only 14 Å. The TMDs of these structures
are oriented in an “outward-facing” arrangement with a
relatively polar cavity exposed to the extracellular space. This
orientation has been equated with a “drug release”
conformation.
18,19 ATP hydrolysis and the release of ADP
and Pi may cause a change to an “inward” orientation that
reveals high-aﬃnity drug binding sites.
19 Four structures of the
bacterial lipid ﬂippase, MsbA,
20 show dramatic conformational
diﬀerences that have been equated with diﬀerent stages of the
transport mechanism.
20 These include structures with TMDs
opened inward with slightly disengaged NBDs [Protein Data
Bank (PDB) entry 3B5X], and structures with an opened
outward DBS and fully engaged, dimerized NBDs (PDB entries
3B5Z, 3B5Y, and 3B60). One of these structures is noteworthy
in having ADP-Vi, a transition state analogue, bound in one of
the nucleotide binding sites (PDB entry 3B5Z). In addition,
one MsbA structure displayed fully disengaged NBDs with
catalytic glutamates separated by more than 65 Å, similar to the
mouse Pgp discussed above.
Powerful new computational schemes for a more complete
analysis of protein dynamics and ligand binding have recently
been reported.
23−25 These methods begin with molecular
dynamics (MD) simulations from which representative “non-
redundant” structures are identiﬁed using statistical meth-
ods.
23−26 These methods were applied here using targeted MD
simulations of Pgp with four crystal structures of homologues
of Pgp as targets. In this approach, the current position of each
atom is steered toward target coordinates derived from the
crystal structures via application of a force vector calculated to
decrease the distance between present and target positions.
27,28
Targeted MD allows sampling of large conformational changes
that would normally be inaccessible because of the large energy
barriers that likely lie between such conformations and
limitations in computational time. The resulting nonredundant
intermediate structures derived from these targeted MD
calculations were then used in ligand docking calculations to
elucidate binding of the ligand to the diﬀerent structures. This
approach combines the conformational information gained
from MD with ligand docking and accounts for the dynamic
movement of both protein and ligand.
In this paper, homology models of human P-glycoprotein
have been applied to targeted MD simulations to move the Pgp
structure through conformations that were based on just a few
known, catalytically relevant crystal structures. These crystal
structures are germane to the dynamics of transport catalysis by
Pgp, because the transporter very likely transitions through
structures that are similar to these individual states during
catalysis. In this study, 26 novel, nonredundant catalytically
intermediate conformations were identiﬁed using the targeted
molecular dynamics techniques. Ligand docking studies over
the dynamic trajectory of the 26 catalytically relevant structures
were performed, and results were consistent with published
biochemical and biophysical ﬁndings. The results of these
studies are discussed with regard to the molecular mechanisms
that underlie the drug binding and drug transport mechanisms
of human P-glycoprotein.
■ EXPERIMENTAL PROCEDURES
Materials. The Visual Molecular Dynamics program suite
(VMD)
29 was extensively used in this work. MD experiments
were performed using NAMD.
30 XPLOR-NIH was employed
for simulated annealing calculations.
31,32 Secondary structures
were identiﬁed using STRIDE.
33 Procheck version 3.5.4 was
used to validate the geometry of calculated protein structures.
34
Small commodity computing clusters, the High Performance
Computing Cluster at SMU, and the Ranger cluster at the
Texas Advanced Computing Center were used for calculations.
Modeling Human Pgp with Sav1866. Models for human
P-glycoprotein were created using sequence homologies
between Sav1866
18 and the protein sequence of Pgp (Uniprot
entry P08183). After the alignment of sequences with
clustalW,
35 the coordinates of non-hydrogen backbone and
Cβ atoms of the structural template Sav1866 (PDB entry
2HYD,
18 with ADP bound) that were homologous to Pgp
residues were renamed as Pgp residues. Corresponding
backbone and side chains were then built using psfgen.
29 The
linker that connects NBD1 and TMD2 in the human Pgp,
residues 632−693, was not included in these models. Lists of
distances and topologies (helical or sheet) were compiled with
VMD. These lists were employed as distance or torsional
restraints for use in simulated annealing using XPLOR-
NIH.
31,32 A total of 94414 distance and 1475 dihedral restraints
were used in these calculations, and several hundred annealing
experiments were performed. The Pgp structure that had the
fewest distance and dihedral restraint violations was then
positioned into a 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC) bilayer, and water (TIP3 model) and ions
(Na+ and Cl−) were added using the solvate and autoionize
functions in VMD. ATP, Mg2+, and a catalytic water were
substituted for ADP at NBD1, and a Mg2+ ion was added at
NBD2 (see Results). The ﬁnal system contained two protein
chains, one ATP, one ADP, two Mg2+ ions, six Na+ ions, 17 Cl−
ions, 203 POPC phospholipids, and 24689 water molecules
(120016 total atoms). Energy minimizations to eliminate any
van der Waals clashes between atoms and poor geometries of
residues and extensive equilibrations of the lipid, the water, the
protein, and the entire system were performed using NAMD to
ensure the integrity of the system before any simulation
experiments were performed.
Molecular Dynamics Simulations. MD simulations used
NAMD 2.6
30 and the CHARMM27 force ﬁeld
36 with constant
temperature and pressure (NPT ensemble) in a periodic cell
using Langevin temperature and pressure control, as well as
particle-mesh Ewald electrostatic calculations at 310 K.
Targeted MD simulations
27,28 were performed using target
coordinates derived from mouse Pgp,
17 Sav1866,
18 and MsbA
structures (PDB entries 3B5X and 3B5Z).
20 Structures were
aligned using STAMP,
37 and the coordinates of homologous
Cα atoms for each structure then functioned as target
coordinates in sequential simulations. Targeted MD simu-
lations were performed in NAMD using tcl scripts that applied
forces to Cα atoms that were directed at individual target
coordinates. The magnitudes of these forces were calculated to
be inversely proportional to the distances separating the
targeted Cα atoms and the target coordinates.
Clustering of Dynamic Structures. The structural
redundancy inherent in the molecular dynamics simulations
was reduced using the methods applied to protein structures
introduced by Luthey-Schulten.
38 Coordinate ﬁles from
targeted MD calculations were saved at ∼1 ps intervals.
These ﬁles were then analyzed for similarity using the QR
factorization methods
38 built into Multiseq,
26 which employed
STAMP structural alignments.
37 Phylogenetic trees using QR
clustering (or in other cases rmsd clustering) were also
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26 Nonredundant structures were
selected using a QH cutoﬀ of 0.2
38 or an rmsd cutoﬀ of 2 Å.
In Silico Drug Docking Analyses. AutoDock 4.2
39−41 was
used with each of the nonredundant structures identiﬁed from
the targeted MD clustering experiments. Grids were calculated
using a 0.375 Å spacing in a 126 Å3 cube. Two overlapping
grids were used in each set of docking experiments. For each
ligand, 100 genetic algorithm experiments were performed with
Figure 1. Phylogenetic tree representations for human Pgp structures derived from target molecular dynamics trajectories. QR factorizations on the
N-terminal half (left) and C-terminal half (right) of the human P-glycoprotein targeted molecular dynamics trajectory were performed as described
in Experimental Procedures. A ΔQH cutoﬀ of 0.2 (solid vertical lines) resulted in the selection of 16 representative structures in each half of the
protein. Selected representative trajectory structure numbers are shown on the inside of each tree. The locations of the four targets (fully opened
inward, partially opened inward, partially opened outward, and fully opened outward) are also indicated with text. The trajectory frame numbering
was sequential from fully opened inward to fully opened outward conformations. Model numbers are arbitrary other than indicating the sequential
order of the structure snapshots.
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and 27000 generations. The preferred mode of binding of each
ligand was determined using ligand results clustering at rmsd
values of ≤2.0 Å. This type of analysis takes advantage of one of
the strengths of the technique (the determination of the mode
of binding of the ligand to the protein) while minimizing the
reliance on a relative weakness of the method (the estimation
of binding aﬃnity).
40,42,43 The clustering of ligand docking
results by rmsd puts each of the 100 independent docks per
experiment per ligand into a set of docking results based on
ligand geometry and position in space. These cluster sets can
have anywhere between 1 and 100 members in them,
depending on the results of the experiments. The cluster set
with the greatest number of members is considered here to be
the preferred docking cluster because it is the most
reproducible docking pose of binding of the ligand to the
protein. In general, only the preferred docking cluster for each
ligand will be discussed.
■ RESULTS
Catalytic Conformations of Human P-Glycoprotein.
The 3.0 Å resolution, “partially opened outward” Sav1866
structure was used as a structural template in simulated
annealing calculations to generate an all-atom homology model
of human Pgp. Sav1866 was chosen as a template because of its
relatively high resolution and because, having a sequence 53%
homologous to that of human Pgp, it can be regarded as a close
relative.
18 Comparison of the secondary structure topologies of
Sav1866 with those of mouse Pgp
17 demonstrated highly
conserved folds for both transporters. Human Pgp structures
were built using distance and torsional restraints obtained from
Sav1866 that were then applied to the human Pgp sequence.
The best Pgp model produced had less than 0.2% distance
restraint violations (159 of 94414), less than 0.5% torsional
violations (8 of 1475), and an rmsd of 0.96 Å between Cα
atoms of the model and template. An overall G factor score
(Procheck
34) of 0.03 suggested that individual residues
approached ideal geometries. A total of 15 of 1190 residues
were found in disallowed regions of Ramachandran plots
(1.3%). Prior to MD simulations, ATP, Mg2+, and water were
substituted for ADP at NBD1. This added water was observed
to engage the catalytic glutamyl residue (E556) in what
appeared to be a chemically competent manner during energy
minimizations. In subsequent MD trials, this nucle-
otide·Mg2+·H2O complex was retained in NBD1, indicating
that these interactions were relatively stable (data not shown).
Similar engagement of catalytic glutamyl 1201 with ATP, Mg2+,
and H2O placed at NBD2 was not observed. Only the ADP and
Mg2+ were therefore retained at NBD2.
Targeted Molecular Dynamics of Human Pgp.
Targeted MD simulations were performed on the human Pgp
model in attempts to elucidate possible catalytic transitional
states. Targeted MD allows the sampling of large conforma-
tional changes that would not be computationally accessible
with other techniques. In this work, the Sav1866-derived
human Pgp structure was initially pushed toward the “fully
opened inward” mouse Pgp conformation (PDB entry
3G60).
17 Subsequent simulations sequentially targeted the
“partially opened inward” MsbA structure (PDB entry 3B5X),
20
the Sav1866 partially opened outward, fully engaged NBDs
conformation (PDB entry 2HYD
18), and ﬁnally the MsbA
transition state structure with fully engaged NBDs and “fully
opened outward” DBS (PDB entry 3B5Z).
20 Using the force
constants described in Experimental Procedures, the close
approach of the human Pgp model to each of the crystal
structure targets was achieved with rmsds for targeted Cα
atoms and modeled atoms varying between 0.4 and 0.6 Å for
each of the four target structures.
Several striking characteristics of the conformational changes
that Pgp undergoes as it moves from the fully opened inward to
fully opened outward conformations were observed in these
simulations. Videos of these conformational changes are
presented as Figures S1 and S2 of the Supporting Information.
One can clearly see the twisting movement of the NBDs
relative to the TMDs when engagement of the NBDs occurs.
From the extracellular view of the transmembrane domains,
one can also clearly observe a gradual rearrangement of TM
helices that orient the TMDs from inward-facing to outward-
facing structures. In addition, a dramatic widening of the TMDs
into the extracellular space occurs, which is very clearly
observed when the fully opened outward transition state is
adopted.
Reducing Structural Redundancy in the Targeted
Molecular Dynamics Simulations. The analysis of protein
structures using multidimensional QR factorization to remove
redundancy in the structure set has been pioneered by Luthey-
Schulten.
26 Such analyses were performed as described in ref 23
using the N-terminal and C-terminal halves of Pgp obtained
from the targeted MD simulations to identify a small set of
structures that represent the entire simulation trajectory. Using
these techniques to cluster similar structures allows the creation
of structurally based phylogenic trees that aid in choosing
nonredundant samples. Two such factorizations performed on
the TMD1−NBD1 and TMD2−NBD2 halves of Pgp over the
complete targeted MD trajectory were performed to identify
“unique” or “nonredundant” conformations of the transporter.
A ΔQH cutoﬀ of 0.2, where QH is a measure of structural
similarity,
26 resulted in 16 representative nonredundant
structures for each of the two analyses of the Pgp-targeted
MD trajectory. A total of 26 unique nonredundant con-
formations for the complete Pgp structure were therefore
obtained from these simulations (six structures were common
to each of the N- and C-terminal QR clusterings). Figure 1
shows the results of these factorizations performed on the
NBD1−TMD1 and NBD2−TMD2 motifs over the complete
trajectory. Similar results were obtained from rmsd clustering
with a 2.0 Å cutoﬀ (not shown). The 26 nonredundant
conformations identiﬁed via QR factorization were used in all
subsequent analyses of the conformational changes and in
ligand docking studies presented here.
Figure 2 (■) shows the separation distances of the
catalytically important glutamyl residues 556 and 1201 in the
two NBDs over the simulated TMD trajectory. These residues
are thought to activate the catalytic water of hydrolysis at the
active sites and are therefore at a crucial position in the catalytic
sites. One can see that as the simulation progresses from wide
open inward to partially opened inward (two leftward arrows in
the ﬁgure), the separation of the catalytic glutamyl residues,
although they do move throughout this phase of the trajectory,
remains relatively constant at approximately 30 Å. These initial
movements of the transporter correspond to a rotation of the
two NBD domains relative to each other while the drug binding
domain (DBD) undergoes a transition from fully open inward
to partially opened inward states. During this initial transition,
two residues of the DBD implicated in verapamil binding [F728
and V982 on TM7 and TM12, respectively (Figure 2, ●)]
9,12
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simulation progressed from partially opened inward to fully
engaged NBDs with partially opened outward DBD (second
and third arrows from the left), the degree of “engagement” of
the two NBDs as judged by catalytic glutamate separation was
reduced fairly smoothly from 34 to 17 Å (■). This smooth
closure between residues 556 and 1201 continued through to
the ﬁnal “transition state” targeted structure with a fully opened
outward DBD where the minimal separation of 15 Å between
these catalytically important residues was observed. The
progression over these ﬁnal transitions was signiﬁcantly
diﬀerent for the verapamil-associated residues of the DBD.
This residue pair underwent a transition to a minimal
separation of ∼14 Å in the fully engaged NBD−partially
opened outward structure (third arrow from the left) but then
opened up signiﬁcantly by ∼8 Å to a >22 Å separation. This
ﬁnal conformational change represented a dramatic opening of
the verapamil-associated residues as the ﬁnal transition state
target was approached and may represent the “export” state of
the transporter.
The dramatic opening in the DBD observed for residues 728
(TM7) and 982 (TM12) was also observed when the
extracellular ends of the transmembrane helices were examined
in a pairwise fashion as shown in Figure 3. This ﬁgure presents
the movement of homologous α-helices from the N-terminal
and C-terminal halves of the drug binding domains on both the
extracellular ends of each pair of transmembrane helices (1/7
through 6/12) and the intracellular cytoplasmic ends of these
helices (Figure 3, top and bottom panels, respectively). As
observed for the NBD catalytic glutamyl residues and
verapamil-associated residues in Figure 2, the initial part of
the simulation proceeds with gradual movements of the drug
binding domain helices, especially for transitions that occur
between the wide open to the cytoplasm and partially open to
the cytoplasm targets (ﬁrst two arrows from the left). These
movements correspond to the expected opening of the
extracellular helices and closing of the intracellular helices as
the transporter undergoes a transition from wide opened
inward to partially opened inward conformations. During the
next transitions between the partially opened inward and fully
engaged NBDs−partially opened outward conformations and
ﬁnally the transition state fully opened outward conformations,
the extracellular ends of helices 1/7 and helices 2/8 continued
the relatively smooth trend of opening outward all the way
through to the ﬁnal transition state conformation of the
simulation.
A dramatic opening and widening movement of the
extracellular ends of the four remaining helical pairs (3/9, 4/
10, 5/11, and 6/12) was observed, however, as the transporter
approached the ﬁnal catalytic transition state structure from the
engaged NBD−partially opened outward state (Figure 3, top
panel). These latter movements appeared to be very similar to
those presented in Figure 2 for the verapamil-associated
Figure 2. Movement of catalytically important residues of the human
P-glycoprotein from target molecular dynamics simulations. Shown are
the distances that separate two glutamyl residues that have been
implicated in the catalytic activation of the waters of hydrolysis
(residues 556 and 1201) and two residues of the drug binding domain
that have been implicated in verapamil binding (residues 728 and
982). The distances that separate these two pairs of residues were
calculated for each of the 26 nonredundant Pgp structures over the
course of the simulation.
Figure 3. Coordinated movements within the drug binding domain of
the human P-glycoprotein from target molecular dynamics simu-
lations. The ﬁgure presents the distances between the ends of
homologous α-helices in each half of the drug binding domain. The
top panel represents paired helical movements on the external face of
the membrane for helices 1/7, 2/8, 3/9, 4/10, 5/11, and 6/12 as
separation distances between residues 72 and 732, 112 and 753, 210
and 853, 217 and 856, 318 and 961, and 328 and 972, respectively.
Similarly, in the bottom panel, helical movements at the cytoplasmic
end of helical pairs 1/7, 2/8, 3/9, 4/10, 5/11, and 6/12 very near the
NBDs were quantitated as the separation distances between residues
51 and 711, 156 and 797, 168 and 811, 256 and 895, 270 and 916, and
368 and 1010. Distances were calculated for each frame using tcl
scripts in VMD. The x-axis numbering represents the 26 non-
redundant trajectory-derived structures identiﬁed in Figure 1,
numbered sequentially from the wide opened inward to wide opened
outward targets. The double-headed arrows show the structures closest
to the crystal structures that were used as targets, i.e., from left to right
in the ﬁgure, the fully opened inward, mouse Pgp 3G5U
17 targeted
structure; the partially opened inward structure from the MsbA
3B5X
20 structure; the opened outward structure from the Sav1866
2HYD
18 targeted structure; and the fully opened outward structure of
the MsbA ADP-Vi-bound 3B5Z
20 structure, respectively.
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changes in this phase of the simulation were observed for
helices 4 and 10 and helices 5 and 11. The extracellular ends of
these helices separated over the entire simulation by 17 and 24
Å, respectively. Similar extents of movement in the direction of
closing of the cytoplasmic NBD-associated helical ends of these
same helices (20 and 17 Å, respectively) were observed. It can
be seen, however, that the movement on the cytoplasmic NBD
ends of these helices occurred with a more constant rate
(Figure 3, bottom panel), showing much less if any of the
dramatic movement apparent in the extracellular parts of the
DBD (Figure 3, top panel). Analogous changes in the other
helical pairs (helices 3/9 and helices 6/12) were also observed,
but the magnitudes of these changes were smaller than that of
the changes observed for helices 4/10 and helices 5/11 (not
shown).
Correlation with Previously Observed Helical Move-
ments during ATP Hydrolysis. In a series of studies,
44−46
Loo, Clarke, and co-workers were able to show that
transmembrane helices 11 and 12, which have been implicated
in drug binding,
6−11 undergo movement during ATP
hydrolysis. In a very large mutational cross-linking study
designed to investigate helical interactions with TM11, these
authors showed that of 350 possible double-cysteine mutations
in TM11 and TM1, -3, -4, -5, or -6, cross-links were observed
between only TM1 and TM11 and that all ﬁve of the observed
cross-links formed only if the transporter turned over via ATP
hydrolysis.
44 In related work involving disulﬁde bond
formation
45 or cross-linking with an extended multifunctional
maleimide compound,
46 similar observations were made for
pairs of residues present on TM6 and -12. Most of the cross-
links observed in these latter studies also required ATP
hydrolysis to form.
The dynamics of the interacting pairs of residues implicated
in these ATP hydrolysis-dependent cross-linking studies were
analyzed in the simulations made here in attempts to further
investigate these helical movements. Relatively complex
movements of TM1 and -11 and TM6 and -12 were observed
as the transporter moved from conformations with the DBD
wide open inward to conformations that were wide open to the
outside (see Figures S3−S5 of the Supporting Information).
These complex movements proceeded in three distinct phases.
To start, as the transporter moved from a conformation with
DBD wide open to the inside with fully disengaged NBDs (see
frame 0 in Figures S3−S5 of the Supporting Information) to a
conformation with the DBD partially opened to the inside
(frame 12 in the ﬁgures), each of the Cα atoms of the cross-
linked residue pairs identiﬁed in refs 44−46 moved from near
minimal separation to near maximal separation. As the
simulation progressed from the partially opened inward to
partially opened outward conformation (frames 12−22 of
Figures S3−S5 of the Supporting Information), movement of
the DBD helices to near minimal separation of the identiﬁed
cross-linked residues of TM1 and -11 and TM6 and -12
occurred. Finally, as the transition state conformation with fully
opened outward DBD was reached (frame 26 of the ﬁgures),
the cross-linked residues once again separated to large and in
some cases near maximal values. It is clear that if the
transporter ground state in the absence of turnover is at or
near the partially opened inward conformation, cross-linking of
the paired cysteine residues of TM1 and -11 and TM6 and -12
would be unlikely, because this conformation showed maximal
separation of the Cα atoms of the cross-linked residues. It is
reasonable to infer that catalytic turnover would likely be
required to move the helices into closer contact so that
disulﬁde bond formation could occur. The simulations reported
here are consistent with the observations of Loo et al.
44−46
about the movements of TM1 and -11 and TM6 and -12.
Mechanistic Insights from the TMD Analyses. Analysis
of the structures of the transporter during the TMD simulation
phases where the conformation changes from an intracellularly
oriented DBD to one with partially and then fully extracellularly
Table 1. Close Contacts between NBD Residues and Coupling Helices
a
coupling helix NBD residues in contact with CH residues NBD comments
CH1 (residues 160−167) 371, 372 NBD1 residues of NBD1 loop C-terminal to TMD helix 6
401, 402 NBD1 residues of A-loop
443, 444 NBD1 residues C-terminal to Walker A
1174, 1175 NBD2 residues N-terminal to signature sequence
CH2 (residues 260−267) 1118 NBD2 residue of NBD2 loop C-terminal to TMD helix 12
1077 NBD2 Walker A
1081, 1084, 1086, 1087 NBD2 helix following Walker A
1110, 1114−1117, 1119−1123 NBD2 residues at and around Q-loop
1133, 1135 NBD2 loop that returns to CH2 located after Q-loop
1188, 1189, 1192 NBD2 residues just after signature sequence and just before Walker B
1200 NBD2 Walker B
CH3 (residues 801−808) 1015−1017 NBD2 residues on NBD loop at top of helix 12
1044−1046 NBD2 residues at A-loop
1086−1088 NBD2 residues C-terminal to Walker A
523, 526, 527 NBD1 residues of Walker B
CH4 (residues 901−911) 378 NBD1 residue on NBD1 loop at top of helix 6
438 NBD1 helix following Walker A
441, 443 NBD1 loop after the helix following Walker A
476, 478−480, 491−493 NBD1 residues at and around Q-loop
476, 478−480, 491−493 NBD1 residues C-terminal to Q-loop, including the short helix just after Q-loop
527, 543, 547 NBD1 residues before Walker B
aResidues in the nucleotide binding domains (NBDs) found to be within 2.5 Å of coupling helix residues in any of the 26 nonredundant Pgp
structures were identiﬁed using tcl scripts in VMD.
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as testable hypotheses in future studies. Figure S1 of the
Supporting Information sequentially shows each of the 26
nonredundant protein structures identiﬁed from the targeted
MD trajectory as a video animation. An alternate video with
color-coded transmembrane helices (Figure S2 of the
Supporting Information) has also been included for easier
identiﬁcation of individual substructures. In both videos,
concerted movements of the NBDs with the DBD α-helices
can be observed. One feature that was very apparent in these
simulations was the dramatic widening of the extracellular ends
of transmembrane helices 3/9, 4/10, 5/11, and 6/12 (as
quantitatively shown in Figures 2 and 3). As Dawson and
Locher pointed out previously for the Sav1866 protein,
19
helices 2/8 and 3/9 and helices 4/10 and 5/11 of the DBD of
the transporter are connected at the interface with the NBDs by
short α-helices that are oriented parallel to the membrane and
were termed “coupling helices” (CHs) by these authors. The
equivalent residues that make up the coupling helices in the
human Pgp transporter are 160−167 (CH1), 260−267 (CH2),
801−808 (CH3), and 903−911 (CH4). Because these helices
are the connection points between the power-generating NBDs
and the structures of the DBD that undergo the energy
requiring conformational changes that transport ligands across
the membrane, it is reasonable to infer that movement of these
coupling helices is critical for the pumping mechanism of the
transporter.
Consistent with this inference, in the simulations performed
here it appeared that the coupling helices at the NBD interface
moved in concert with the nucleotide binding domains as the
transporter underwent the transition from the partially opened
inward to partially opened outward conformation. This
concerted movement continued relatively smoothly as the
fully opened outward−transition state conformation was
reached. An elucidation of the structures of the NBD that
interacted directly with the coupling helices during the targeted
MD simulation at this transmission interface was conducted,
and the results are listed in Table 1. Consistent with the
analyses of the Sav1866 structure conducted in ref 18 and with
work that indicated close contact and movement between the
CH2−NBD2 and CH4−NBD1 fragments,
47 coupling helices
CH1 and CH3 each contacted both the NBD1 and NBD2
domains while coupling helices CH2 and CH4 interacted only
with the NBD domains of the opposite halves of the
transporter [NBD2 and NBD1, respectively (see Table 1)].
From the results presented in Table 1, it can be seen that CH2
and CH4 made many more contacts with the NBDs than did
CH1 and CH3 during the simulations. It may be that the CH2
and CH4 contacts are structurally more important in driving
the necessary conformational changes in the DBD to eﬀect
pumping of substrates than are those contacts made between
the NBDs and CH1 and CH3.
It seemed to be of interest to propose a mechanism for the
dramatic movements of the extracellular face of the DBD that
occur during the ﬁnal conformational change to the “transition
state−fully opened outward” structure. Figure S6 of the
Supporting Information presents a video that allows the
visualization of the conformational changes that occurred in
the transporter during this transition. Helices 4 and 5 and
helices 10 and 11 prior to reaching the catalytic transition state
conformation possessed a pronounced bend that produced an
arclike shape that was especially pronounced in the fully
engaged NBD−partially opened outward structures. This
curvature in essence kept the extracellular face of the DBD
closed or only partially opened at the inward opened and
partially opened outward stages of the simulation. As the
catalytic transition state was approached, however, and as CH2
and CH4 moved the ﬁnal few angstroms in concert with the
NBDs, helices 4 and 5 and helices 10 and 11 were positioned in
a manner that appeared to allow these helices to adopt much
more straightened and more ideal α-helical conformations. This
straightening of helices 4 and 5 and helices 10 and 11 resulted
in the dramatic widening of the distance between the
extracellular ends of these helices (see also third and fourth
arrows from the left in Figures 2 and 3). As the catalytic
transition state was being approached, the N-terminal ends of
CH2 and CH4 were observed to move away from each other
by 2.1 Å, while the corresponding C-terminal ends moved
together by ∼1.7 Å. This twisting motion of these coupling
helices is very likely driven by nucleotide binding domain
conformational changes as bound ATP approaches its hydro-
lytic transition state. This relative motion of coupling helices 2
and 4, although very slight (comprising relative movements of
≤2 Å), is hypothesized here to allow the NBD-located ends of
helices 4 and 5 and helices 10 and 11 enough movement to
allow the remainder of these helices to straighten out into a
more ideal α-helical structure. This associated straightening of
helices 4 and 5 and helices 10 and 11 and the consequent
coupled movement of helices 3 and 9 (which are connected via
very short externally located loops with helices 4 and 10) and
helices 6 and 12 (which are connected to helices 5 and 11 by
short externally located loops) is hypothesized to move the
external face of the drug binding domain in a coordinated
manner to its fully opened catalytic transition state con-
formation. Less relative movement of helices 1/7 and helices 2/
8 during this approach to the catalytic transition state is
apparent and is consistent with the quantitative data of Figure 3
that show most of the dramatic opening of the drug binding
domain to the outside occurring with helices 4/10, 5/11, 3/9,
and 6/12. Although these simulations clearly cannot demon-
strate the driving force for these rearrangements, it seems
evident that the energy input for these movements must
originate with rearrangements at the NBDs with nucleotide
binding and/or hydrolysis and the consequent movement of
the contacted coupling helices.
Drug Docking to Human Pgp. The 26 nonredundant Pgp
structures derived from the targeted MD simulations were used
in drug docking studies to analyze binding of the ligand to
dynamic transitions of human Pgp structures. The ligands
analyzed were selected because they are known to bind Pgp, are
transport substrates of Pgp, or inhibit Pgp (Table S1 of the
Supporting Information). Two molecules, ADP and PPi, served
as negative controls for Pgp docking because they do not ﬁt the
criteria of good Pgp transport substrates. Two of the Pgp
ligands used here are sulfur analogues of the selenium-
containing cyclic peptide inhibitors, QZ59-RRR and QZ59-
SSS, that were shown previously to crystallize to three closely
placed but diﬀerent binding sites in mouse Pgp.
17 The docking
of these QZ59 analogues to the fully opened inward
conformation of Pgp was closely analyzed here for validation
of the human Pgp structure and targeted MD. Figure 4A shows
the results of the initial docking to human Pgp. Comparison
with the mouse crystal structure (Figure 4B)
17 indicates
extensive similarities in the location of binding sites for the
inhibitors. A clear correlation of both the positioning of the
drug within the pockets of the two transporters and the
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observed (Figure 4, human Pgp in panel C vs mouse Pgp in
panel D). Although the mode of binding to human Pgp and the
mouse structure is not identical, there are clearly very similar
interactions with homologous residues. Drug binding in the
proximity of the partial binding site for QZ59-SSS identiﬁed by
ref 17 was observed here as a less populated docking cluster
(data not shown). Nineteen of the 21 residues identiﬁed by ref
17 as interacting with QZ59-SSS were within 3.5 Å of the
preferred docking cluster for the QZ59-SSS sulfur analogue in
these experiments (Figure 4C,D, bottom). Tryptophan 315 and
threonine 837 were >4 Å from the preferred docking cluster for
the QZ59-SSS sulfur analogue in the Pgp model. The results
from these initial docking experiments strongly support the
validity of the structural modeling as well as the drug docking
simulations presented here.
Figure 5 shows the docking of the QZ59-RRR analogue to
three neighboring conformational states within the dynamic
trajectory of Pgp near the fully opened inward conformation
(Figure 5A−C, left). For comparison, the mouse Pgp structure
in complex with QZ59-RRR is shown in each right-hand
panel.
17 The positions of side chains in previous and/or
subsequent frames are indicated in the ﬁgure with thin lines. All
12 of the residues (Figure 5D) that make up the QZ59-RRR
“middle” binding site
17 are within 3.5 Å of the QZ59-RRR
analogue docked into the human fully opened inward
conformation, indicating very similar docking of the RRR
analogue compared to that seen in the mouse Pgp crystal
structure. Comparison of docking to human Pgp in panels A
(left), panel B (left) and panel C (left) shows what could
represent potential aromatic gates to the drug binding site.
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These results again support the results of docking and
simulation reported here as valid representations of the
human Pgp transporter.
Drug−Protein Interaction Dynamics. Diﬀerent modes of
drug interaction throughout the transmembrane regions of the
DBS were found in docking experiments performed on the 26
nonredundant Pgp structures using 21 potential transport
ligands (see Table S1 of the Supporting Information). It seems
noteworthy that the fully opened outward conformations did
not show preferential docking in the extracellular half of the
transmembrane regions, potentially reﬂecting structural desta-
bilization of ligand binding to the DBS as Pgp adopts the
opened outward conformation (see below). Docking of either
PPi or ADP was found exclusively outside of the trans-
membrane DBS and was limited to a narrow band around the
outside of the protein at the cytoplasmic face of the membrane
(data not shown). Representative results for docking of
daunorubicin to four conformations from the fully opened
inward to fully opened outward states are shown in Figure 6.
There appear to be several preferred docking sites that are
dependent on the conformation of the protein. While both the
partially opened inward and partially opened outward
conformations preferred daunorubicin docking to the extra-
cellular half of the DBS, the fully opened outward conformation
showed only preferred docking in the cytoplasmic half of the
DBS. This may reﬂect structural destabilization of ligand
binding to the extracellular half of the DBS as it adopts the
opened outward conformation and may be mechanistically
important as a “release” state of the transporter.
Figure 7 summarizes the docking results obtained using all of
the ligands tested here by showing the residues of the DBS that
were ≤3.5 Å to any of the best docked ligand clusters (colored
red). Figure 7A shows the conformational opening of the
extracellular parts of Pgp and the exposure of the drug binding
Figure 4. Docking of cyclic inhibitor analogues, QZ59-RRR (blue)
and QZ59-SSS (red), to fully opened inward Pgp conformations. (A)
Human Pgp showing the preferred docking clusters, the most
reproducible drug docking clusters for two simulation frames at the
fully opened inward conformation, superposed. (B) Mouse Pgp
structures from ref 17 with the QZ59-RRR (blue) and QZ59-SSS
(red) cyclic inhibitors bound. Transmembrane regions of both
proteins are colored silver. (C) The top portion shows the results
for docking of the sulfur analogue of the QZ59-SSS stereoisomer to
the fully opened inward conformation of human Pgp. Residues within
3.5 Å of the three most reproducible docking clusters are shown as
licorice colored by atom type. The most reproducibly docked QZ59-
SSS analogue is shown bound as black licorice. (D) The top portion
shows the mouse Pgp structure from ref 17 with QZ59-SSS bound
(black). Amino acids identiﬁed by Aller et al.
17 to be involved in drug
binding are shown as licorice colored by atom type. The bottom
portions of panels C and D identify the residue numbers of the amino
acids shown in the top panel (C, human numbering, and D, mouse
numbering). Note that each residue shown in either panel has its
homologue shown in the same relative position in the other panel.
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fully opened inward to fully opened outward states. Figure 7B
depicts Pgp from the cytoplasmic side of the drug binding
domains (the nucleotide binding domain portions were
removed for the sake of clarity). This row of images
demonstrates that the drug binding surfaces of Pgp are exposed
to the cytoplasmic face of the membrane and cytoplasm in the
fully opened inward conformation and that the drug binding
surfaces become progressively less accessible to the cytoplasm
as the transporter moves toward the fully opened outward
conformation.
In analyses designed to determine whether inhibitors of Pgp
interacted with the transporter diﬀerently than transport
substrates, the close contacts between protein and docked
ligands of the preferred docking clusters on all 26 non-
redundant Pgp structures of the inhibitors and transport
substrates listed in Table S1 of the Supporting Information
were compared. Of the 46 ≤3.5 Å contacts between ligands and
residues of the drug binding domains, one inhibitor (biricodar)
was found to contact a residue on TM6 (F335) that was not
within 3.5 Å of any other docked inhibitor or substrate. Several
diﬀerent substrates and inhibitors, however, contacted the
neighboring residues L332 and F336 of TM6, making it
unlikely that residue 335 was of special interest in establishing
Pgp inhibition. (A text ﬁle containing a table listing Pgp
residues within 3.5 Å of any docked inhibitor or transport
substrate from these studies can be downloaded from the
Supporting Information.) Of the 39 ≤3.0 Å contacts between
ligands and Pgp residues of the drug binding domains, no
inhibitor was found to contact a residue that was not also
contacted by one or more transport substrates. These results
suggest that no diﬀerences between the inhibitor or modulator
binding to Pgp and the normal transport substrate binding to
Pgp could be detected using the ligand docking techniques
described here.
■ DISCUSSION
Model Structures of Human Pgp. Homology modeling
using a simulated annealing approach with the 3.0 Å partially
opened outward Sav1866 structure produced a human Pgp
structural model with very few restraint violations and excellent
overall geometries. The Sav1866 crystal structure shows ADP
bound to NBD1 and -2. Substitution of the ADP at NBD1 in
the human Pgp model with ATP, Mg2+, and H2O at NBD1
resulted in stable binding and an orientation that engaged the
catalytic glutamyl 556 in a manner that is consistent with
known general base ATP hydrolysis mechanisms. Very strong
evidence has recently been presented that favors this type of
catalytic mechanism for ABC transporters (see the high-
resolution transition state crystal structures of the maltose ABC
transporter from Oldham and Chen
48 and Senior’s recent mini-
review
21). Similar substitutions of ATP, Mg2+, and H2Oa t
NBD2 did not result in the engagement of the corresponding
catalytic glutamyl 1201, so ADP was retained at NBD2 in all
subsequent simulations. Comparable results were observed in
MD simulations of the BtuCD vitamin B12 transporter where
only one of two ATP molecules was observed to fully engage
with residues of the nucleotide binding sites of the protein.
49
Although the observations that the catalytic glutamyl residue in
NBD1 engaged the bound H2O·ATP·Mg ion complex in these
simulations while the NBD2 glutamyl remained disengaged
from bound substrate are consistent with an alternating sites
mechanism for hydrolysis,
16 a more systematic study of the
phenomena seems to be warranted.
Testing the stability of homology models with MD
simulations has been noted to be critical to the validation of
such models.
50 Indeed, MD simulations of a homology model
based on early crystal structures demonstrated instabilities that
helped point out problems with these structures.
50,51 To
investigate the stability of the Pgp model created here, we
performed NPT dynamics for ∼28 ns. During these
simulations, the secondary structure of Pgp did not signiﬁcantly
change and nucleotides and Mg2+ remained stably bound.
These results suggest that this Pgp model was relatively stable
and had no obvious energetic problems. Since 2007, when
corrected versions of the MsbA structures became available,
several homology models for Pgp have been reported.
50,52−63
Figure 5. Ligand binding to the drug binding pocket of P-
glycoprotein: RRR stereoisomer of the cyclic inhibitor QZ59 binding.
The left side of each panel shows the results of docking to three
sequential TMD frames bracketing the fully opened inward
conformation of the human Pgp model. The right side of each
frame shows the crystal structure of mouse Pgp with QZ59_RRR
bound. (A) First frame of the cyclic peptide docking to human Pgp as
licorice with the positions of side chains in the subsequent two frames
(see panels B and C) shown with thin lines. (B and C) Two
subsequent frames as licorice with previous and/or subsequent frames
shown with thin black lines. Panel D shows the respective positions of
the homologous residues that make up the binding pocket for QZ59-
RRR as identiﬁed by ref 17: left side, human Pgp model; right side,
mouse Pgp crystal structure.
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dx.doi.org/10.1021/bi300299z | Biochemistry 2012, 51, 5125−5141 5133Figure 6. Docking interactions of daunorubicin with the drug binding domain of Pgp. The protein backbone is shown as a tube with the
transmembrane helices colored silver. Daunorubicin is shown in space-ﬁlling representation. Pgp and daunorubicin are shown in the fully open
inward, partially opened inward, partially opened outward, and fully opened outward conformations (from left to right, respectively) in side views
(top) and in views from the extracellular space (bottom). A similar ﬁgure with color-coded helices for ease of identiﬁcation of individual structures is
presented in Figure S7 of the Supporting Information.
Figure 7. Views of the drug binding surfaces of Pgp during catalytic transitions. Amino acid residues observed to approach Pgp within 3.5 Å are
shown with van der Waals surfaces colored red. Secondary structures of the protein are colored black (extramembranous residues) or silver
(transmembrane residues). (A) Extracellular views of Pgp with a viewpoint given by the tip of the arrow in the left image. (B) Views of the drug
binding domains from inside of the cytosolic portion of Pgp with a viewpoint given by the tip of the arrow in the left image (nucleotide binding
domains have been removed for the sake of clarity). Images of the fully opened inward, partially opened inward, partially opened outward, and fully
opened outward conformations are presented from the targeted MD docking trajectory from left to right, respectively. A similar ﬁgure with color-
coded helices for ease of identiﬁcation of individual structures is presented in Figure S9 of the Supporting Information.
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providing additional support for the dynamic transitions
between protein conformations that were investigated here.
Targeted MD of Human Pgp. Several authors have
suggested catalytic mechanisms for Pgp that involve the opened
inward, nucleotide-free conformations that bind drug and
nucleotide, converting the NBDs to fully engaged structures
that then allow relatively large conformational changes that
reorient the TMDs from inward-facing to outward-facing
structures.
3,13,18,19,64−69 There is debate about whether the
wide opened to the cytoplasm conformations observed in some
studies
17,20 are stringently required for transport activity.
Recent studies suggest that Pgp may not need to open fully
to remain active.
70,71 Despite these controversies, a progression
of structures from the “fully opened inward−disengaged NBDs”
of mouse Pgp
17 to the “partially opened inward−disengaged
NBDs” MsbA structure
20 to the “partially opened outward−
fully engaged NBDs” of Sav1866
18 and ﬁnally the ADP-Vi
transition state MsbA structure showing “fully opened outward
TMDs and engaged NBDs”
20 may approximate conformational
transitions required for catalysis. The experiments presented
here attempt to investigate the possible transitions between
these known conformations by using a targeted MD approach.
Results presented here show that the human Pgp could be
moved very close to each of the four targeted structures. This
simulation of conformational dynamics reveals interesting
subtleties in the catalytic mechanism. The simulations revealed
that the helices that form the drug binding sites of Pgp undergo
large movements in relative position, on both the inside and the
outside of the cell membrane. The largest movements of drug
binding site helices were observed for the pairs of helices 4/10
and helices 5/11. A rather abrupt widening of the drug binding
sites to the outside of the cell was observed as the ADP-Vi
transition state was approached. Twisting of the NBDs as they
fully engage appeared to be coupled to the helical movements
in the TMDs that seem to open the drug eﬄux sites.
Drug Docking to Dynamic Human Pgp. To analyze
binding of the drug and ligand to Pgp over the course of the
catalytic conformational transitions simulated here, a reduction
of the structural complexity of the dynamic trajectories was
required. Luthey-Schulten
26 and McCammon and col-
leagues
23−25 have developed methods for reducing the amount
of conformational information of a MD simulation to a small
set of nonredundant structures that can be used individually in
drug docking experiments. The application of these methods to
the targeted MD simulations of Pgp presented here resulted in
the identiﬁcation of 26 nonredundant transitional structures
that have allowed the analysis of ligand docking over the entire
dynamic transition from the fully opened inward to fully
opened outward states.
Drug docking routines have been shown to be very accurate
in predicting the mode of binding of small molecules to
proteins while not necessarily accurately predicting binding
energies.
40,42,43 In rigorous studies,
40 binding energies for
known ligand−protein complexes had standard errors of ∼2.5
kcal/mol (∼3 orders of magnitude for a typical Kd value). The
results discussed here will therefore emphasize the location and
geometrical interactions between the ligand and protein and
will not stress calculated aﬃnities. Ligand clustering at rmsd
values of ≤2.0 Å was used to classify docked ligands. This type
of clustering analysis reveals docking conﬁgurations that are the
most reproducible as those clusters with the greatest number of
members. It is assumed that these preferred clusters represent
the most favorably bound ligand conﬁguration detected. It
should be noted that several of the ligands analyzed had more
than one well-populated ligand docking cluster, so it should not
be assumed that the docking experiments presented here
suggest that each ligand has only one possible docking
orientation.
It is worth mentioning that the programs used here for ligand
docking allow for fully ﬂexible ligand conformations, which in
combination with docking analyses performed on the 26
nonredundant Pgp conformations results in docking analyses
that fully encompass both the dynamics of ligand binding and
the dynamic conformational changes in the protein throughout
the targeted MD simulation. Docking of the drug to all 26
nonredundant Pgp structures using 21 compounds known to
be transported by or to inhibit transport by Pgp was performed
here. In addition, docking of two compounds, ADP and PPi,
was performed as a control for nontransported ligands. To
validate the structural modeling, the targeted molecular
dynamics, and the docking techniques, we closely analyzed
docking of two compounds in the fully opened inward
conformations, because crystallographic information was
available for the mouse homologue.
17 It should be noted that
these experiments should not be considered typical “redocking”
experiments in which a cocrystallized ligand is removed from a
protein crystal structure and then docked back into the protein
without any intervening dynamic movement of the target
protein. All 26 of the protein structures used here were derived
from very long molecular dynamics simulations at 310 K on
human Pgp without any ligand bound to the drug binding
domains. Despite the diﬀerences between the docking results
presented here and the cocrystallization studies described in ref
17, docking of both the SSS and RRR analogues of the QZ59
inhibitors (Figures 4 and 5) closely reproduced the binding
interactions seen in ref 17. More than 90% of the residues
identiﬁed at the QZ59-SSS inhibitor binding sites in the mouse
model were observed within 3.5 Å of the preferred SSS
analogue binding cluster in the human Pgp, and 100% were
found to be identical for the RRR analogue docking.
Potentially interesting results were obtained for the docking
of the QZ59-RRR analogue to three neighboring conforma-
tional states close to the fully opened inward conformation
(Figure 5). The ﬁgure shows what could represent the QZ59
analogue entering the binding pocket as the side chain of
phenylalanine 978 (top of the binding site) moves out of the
way, allowing access to the homologous pocket shown in the
mouse structure.
17 This movement is reminiscent of the
aromatic gates that control access of ligands to substrate
binding sites and active sites as discussed for acetylcholinester-
ase and membrane transport channels.
72,73 In Figure 5C,
docking of the QZ59S-RRR analogue to Pgp appears to be very
similar to that observed in the mouse transporter. These results
support the hypothesis that the docking and simulation results
reported here are valid representations of the human Pgp
transporter and extend to the postulation of putative aromatic
gating structures in the drug binding sites of Pgp.
Preferred docking clusters for 21 ligands to the 26
nonredundant conformations of Pgp were observed throughout
the transmembrane regions of the DBS for the fully opened
inward to the partially opened outward conformations. In the
Pgp conformations that approached the fully opened outward
ADP-Vi transition state, ligand binding in the extracellular half
of the TMDs was not favored, with preferred docking found in
the cytoplasmic half of the membrane regions. This may be
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binding in the extracellular half of the drug binding site,
coupled with denied access to ligand binding on the
cytoplasmic side, would eﬀectively force release of the ligand
to the extracellular space. It should be noted that the docking
experiments performed here do not require connected
pathways from one ligand cluster to another and in this sense
do not reﬂect actual pathways that a ligand might travel through
the transporter. It will be of interest to follow the molecular
dynamics of a single ligand through the entire conformational
trajectory to directly test this mechanism.
Figure 7 shows the drug binding sites of Pgp by highlighting
any side chain within 3.5 Å of a preferred drug binding cluster
that was found in these studies. One can observe that the drug
binding surfaces are closed oﬀ from the extracellular space in
the fully opened inward conformation, while access to the
extracellular space increases with each step toward the fully
opened outward conformation until a large portion of the drug
binding surface is exposed to the outside of the cell in the fully
opened outward conformation. Figure 7 clearly demonstrates
large conformational changes that allow access of the drug
binding surfaces to change from the cytoplasm toward the
extracellular space as the transporter opens outward. Actual
pumping of the drug transport substrate may or may not reﬂect
a signiﬁcant change in aﬃnity for the drug binding surfaces. If
no change occurs, transport may be eﬀectively a matter of
changed access from inside to outside as the transport
mechanism progresses.
Signiﬁcantly, all of the ligands tested except for ADP and
pyrophosphate were found to bind like daunorubicin to the
DBD of Pgp with multiple preferred ligand clustering sites
found within the transmembrane regions of the DBS. The
results obtained for ADP and pyrophosphate were signiﬁcantly
diﬀerent because neither of these ligands is a good Pgp
transport substrate and neither of these compounds docked
within the drug binding sites of Pgp. These results further
strengthen the docking obtained for the known transport
ligands of Pgp. Very large ligands such as cyclosporine A,
valspodar, and ivermectin were found preferentially docked to
the cytoplasmic half of the transmembrane DBS. This could be
due to the fact that targeted MD trajectory was produced with
unoccupied, “empty” drug binding sites. It may be worth
investigating how much plasticity in structure the DBS
demonstrate when large ligands are incorporated in MD
simulations.
It is clear from the analyses of the residues of Pgp that were
contacted by ligands in these docking experiments that no
apparent diﬀerences in the location of binding of transport
substrates versus Pgp inhibitors or modulators could be
detected using these techniques. These results suggest that
there is not a speciﬁc “inhibitor binding site” located within the
drug binding domain of Pgp and that the mode of inhibition by
these compounds, if binding occurs at the locations deduced
from these docking studies, may be more simply to compete
with transport substrate drugs for the normal pathway(s) of
transport through Pgp.
Correlation of Biochemical Data with Dynamic
Structural Models. Loo, Clarke, and co-workers were able
to show that transmembrane helices 11 and 12 undergo
movement relative to helices 1 and 6 during ATP
hydrolysis.
44−46 In mutational cross-linking studies, these
authors showed that double cysteine mutations introduced
into TM1 and TM11 formed ﬁve diﬀerent disulﬁde cross-links,
but only if the transporter catalytically turned over via ATP
hydrolysis.
44 Similar observations of ATP hydrolysis-dependent
cross-linking of residues on TM6 and -12 were also made by
these investigators.
45,46 The simulations presented here showed
complex relative movements of transmembrane helices 1 and
11 and helices 6 and 12 that proceeded in three distinct phases
(Figures S3−S5 of the Supporting Information). As the
transporter moved from a wide open to the inside to partially
opened to the inside conformation, distances between cross-
linked residues on TM1 and -11 and TM6 and -12 moved from
near minimal to near maximal separations. This was followed
by movements to near minima as the simulation progressed
from the partially opened inward to partially opened outward
conformation. Then as the transition state conformation with
the fully opened outward DBD was reached, the cross-linked
residues on helices 1 and 11 and helices 6 and 12 separated
widely again.
Petersen et al.
74 in a study of 351 naturally occurring cystines
in known protein structures noted that the range of separation
of Cα atoms between two half-cystines was 3.4−7.6 Å with
averages between 5.3 and 5.8 Å depending on the cystine
geometry. The corresponding values for Pgp at its partially
opened inward conformation were approximately 3 times these
averages, and values at the transition state conformation with
the DBD fully opened to the outside were more than twice
these averages, making oxidation of cysteines to cystine unlikely
in these conformations. The minimal values observed in the
simulations for the TM1−TM11 residue pairs were still larger
than the range of naturally occurring cystines reported in ref 74,
however, with Cα−Cα values for the cross-linked residues
ranging from 8.6 to 11.6 Å. Some of this diﬀerence might be
explained by conformational ﬂexibility of the noncovalently
cross-linked helices in these simulations, the fact that two S−H
bonds exist in the mutated and reduced transporters (up to ∼1
Å each depending on the orientation), and the need for
ﬂexibility in the mutated structures to accommodate the
employed oxidant.
Analysis of the geometric orientations of the TM1 and -11
residue pairs suggests that the relative orientation of the
interacting residues as also discussed by Loo and Clarke
44 may
be important in determining whether cystine can form (see
Figure S8 of the Supporting Information). In the conformations
with Cα−Cα distances at or near observed minima, the wide
opened to the inside and partially opened to the outside
conformations (ﬁrst and third panels from the left, respectively,
in Figure S8 of the Supporting Information, equivalent to
frames 0 and 22, respectively, in Figures S3−S5), the helical
surfaces of the interacting residue pairs face each other directly.
In the partially opened to the inside conformation (second
panel in Figure S8 of the Supporting Information), while the
orientation of the helical faces of the interacting pairs would
appear to be acceptable for cystine formation, the Cα−Cα
distances are close to observed maxima, which may preclude
reaction to cystine. In the transition state conformation (fourth
panel in Figure S8 of the Supporting Information), distances
between reactive residues on TM1 and -11 vary between 12.4
and 14.5 Å and are intermediate between the fully opened
inward and partially opened outward minima. A slight
reorientation of the reactive helical faces away from each
other may have made reaction to disulﬁde in this latter
conformation less probable. Loo et al.
44 report that no cross-
linking occurred with transporter preparations that were
inhibited by ATP-Vi (a transition state analogue).
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with the observations of Loo et al.
44−46 of the movements of
transmembrane helices 1 and 11 and helices 6 and 12. The fact
that ATP hydrolysis was required for the cystine formation in
these experiments
44,45 and enhanced other cross-links
46
strongly suggests that the resting ground state of the
transporter is not one of the conformations with minimal
Cα−Cα distances (conformations with the DBD fully opened
to the inside or partially opened to the outside). Catalytic
turnover was likely required to bring the reactive residues into
closer contact and perhaps to supply required conformational
ﬂexibility such that the oxidations to disulﬁde bonds could
proceed. It is a reasonable assumption from refs 44−46 that the
transporter ground state without turnover is at or near a
conformation with a greater separation of the paired cysteine
residues such that cross-linking of these residues in this
conformation would be unlikely. Because the transition state
conformation of the transporter by deﬁnition is quite unlikely
to be the ground state, it is tempting to speculate that the
remaining conformation reported here with cross-linked
residues showing maximal Cα−Cα separation, the partially
opened inward conformation, might be similar to the resting
conformation of the transporter. It also follows that enough
ﬂexibility in the helical backbones is generated during turnover
to position the reactive cysteines close enough for disulﬁde
bond formation in conformations where the paired cysteines
reach minimal separation (either the conformation with the
DBD wide open to the inside or partially opened to the
outside). Interestingly, all but one of the ATPase-dependent
cross-linked residue pairs examined also showed the dramatic
widening as the conformation moved from the partially opened
outward to the fully opened outward transition state (Figures
S3−S5 of the Supporting Information). The single exception
that did not show this eﬀect was the TM6 residue 350−TM12
residue 993 pair. Because these residues are found very near the
center of helices 6 and 12, they would not be expected to show
an opening as dramatic as those of other residues located close
to the exterior. The simulations presented here expand on the
demonstrations by Loo, Clarke, and co-workers that helices 1
and 11 and helices 6 and 12 move during ATP hydrolysis by
presenting three plausible movements of these helices as
catalysis proceeds from transporter conformations fully opened
to the cytoplasm to those fully opened to the extracellular
space.
Loo and Clarke were also able to identify many residues
involved in drug binding using analogues of transport substrates
with sulfhydryl reactive functional groups and cysteine or
arginine scanning mutagenesis. In their studies, protection of
labeling by inclusion of unlabeled substrate was used as the
highest criterion for mapping residues of the DBS. Their work
demonstrated that S222, L339, A342, and G984 were fully
protected by verapamil while I868, F942, and T945 showed less
protection.
75 All of these seven protected residues were found
in this study within 3.5 Å of one or more preferred ligand
docking clusters. Similar studies using dibromobimane
8,76−78
identiﬁed 16 residues that could be protected by transport
substrates. All 16 residues were found within 3.5 Å of a
preferred cluster. A thio-reactive rhodamine B analogue was
used to identify F343,
79 and MTS−verapamil labeling at I306
permanently activated ATP hydrolysis.
80 Both F343 and I306
were found within 3.5 Å of the preferred ligand clusters
elucidated here. F343 in our studies was found to interact very
closely with docked ligands (Figure 5). A novel arginine
mutagenesis approach for rescuing Pgp folding mutants was
used by Loo and Clarke to argue that the bulky arginine side
chain, when present in the drug binding site, mimicked the
rescue of folding of certain mutations by transport substrates
that has been observed.
81 Alteration of known substrate
aﬃnities was taken as evidence that the A302R, F336R,
L339R, G872R, F942R, Q946R, V982R, S993R, and M986R
mutations were at drug binding locations. All of these residues
were found to be within 3.5 Å of the ligand docking sites
identiﬁed in our study. Of the 43 residues identiﬁed by Loo and
Clarke or by Aller et al.
17 to be at the drug binding sites of Pgp,
42 of them (all but T837) were found within 3.5 Å of a
preferred docking cluster of at least one of the drugs tested. In
summary, the docking results presented here are in very good
agreement with the biochemical studies that have elucidated the
speciﬁc residues of the drug binding sites of Pgp.
Mechanistic Implications. Alanine 841, which is found
within 3.5 Å of preferred docking clusters, deserves further
mention. This residue is present on TM9 and appears in our
models to be packed against TM7 during much of the
conformational change from the wide opened inward to the
partially opened outward conformation (Figure 8). Interest-
ingly, however, as the transporter approaches the opened
outward states, A841 moves clear of TM7 as these helices
separate widely (Figure 8). One can clearly observe the opening
of the drug binding domains in these side views (see also
Figure 8. Possible exit gate in the drug binding domain of Pgp. The transmembrane helices of the drug binding domain of Pgp are shown as silver
cartoons, while the extramembranous protein is colored black. Alanine 841 (TM9), V715 (TM7), and G722 (TM7) are shown in space-ﬁlling
representation. A841 is on the right-hand side of each ﬁgure, while V715 and G722 are on the left. V715 is above G722. From left to right are shown
the fully opened inward, partially opened inward, partially opened outward, and fully opened outward conformations, respectively. A similar ﬁgure
with color-coded helices for ease of identiﬁcation of individual structures is presented in Figure S10 of the Supporting Information.
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this represents the opening of a possible transport substrate
“exit gate” in analogy to the entrance gate observed in the
opened inward conformations will have to be conﬁrmed in
future studies. It should be noted that an analogous opening of
TM1 and -3 was observed on the opposite side of the
transporter during the opened inward to opened outward
conformational transitions.
Loo et al.
82 showed in 2003 that diﬀerent transport
substrates diﬀerentially changed the cross-linking patterns
between residues present in the drug binding domain
transmembrane helices. These results were interpreted as
evidence of a substrate-induced ﬁt mechanism for the binding
of diﬀerent transport substrates by Pgp. The simulations
presented here demonstrated the great plasticity of the drug
binding domain structures of Pgp in two diﬀerent and
important ways: the very large movements of the DBD helices
observed as the conformation of the transporter changed and
the localized, more subtle rearrangements of the side chains of
residues surrounding drug binding sites that can be inferred
from the three neighboring conformational states in the QZ59-
RRR analogue binding site (see Figure 5). This report therefore
provides mechanistic support for the proposal that local
rearrangements of residues that interact with transport
substrates together with more global repositioning of helices
between the wide open to the inside to partially opened to the
inside conformations of Pgp would be expected to be able to
accommodate many diﬀerent ligand structures in a substrate-
induced ﬁt mechanism such as that proposed in ref 82.
Several mechanisms for Pgp catalysis and transport have
been postulated.
3,67,83−85 Most have in common the hypothesis
that ATP binding or hydrolysis promotes the association of
NBDs and the adoption of outward-facing DBS, and that
release of hydrolysis products promotes the dissociation of
NBDs and inward-facing DBS. The results from the targeted
MD simulations presented here show some of the details of the
progression of the protein conformations from an initial state,
where the drug binding domains are opened to the cytoplasm
and the nucleotide binding domains are fully disengaged, to a
conformation in which the drug binding domains are fully
opened to the extracellular space and the nucleotide binding
domains are fully engaged. Very large helical movements in the
TMD and the relative twisting of the NBDs as they approach
each other can be observed. It seems reasonable to conclude
that the ADP-Vi transitional state conformation represents a
state of the transporter in the catalytic cycle where the drug
bound in the DBS would be free to dissociate to the
extracellular space. The conformational analyses performed
here support this hypothesis because this conformation shows
the greatest access of the DBS to the extracellular space. The
Sav1866 conformations (with ADP and AMPPNP bound)
appear to exist in a more relaxed state where the outside of the
cell is still accessible from the DBS, but the extent of opening of
the DBS to the extracellular space is smaller. In the simulations
presented here, the ADP-bound Sav1866 conformation was
taken to be an approximation of a conformation with fully
engaged NBDs that followed the partially opened inward
conformation with slightly disengaged NBDs but preceded the
fully opened outward transitional state. It is very likely that this
relaxed opened outward Sav1866 state (or one similar to it)
would also follow the transition state as was originally
suggested.
18,19,65,86 It will be of interest in the future to
perform additional targeted molecular dynamics simulations
with Pgp as new structures of transporters with other
catalytically relevant conformations are discovered.
The dramatic opening of the external face of the DBD as the
transporter moved from the partially opened outward to the
fully opened outward conformation of the catalytic transition
state observed here is hypothesized to occur by a realignment
of coupling helices 2 and 4 caused by movements of the
nucleotide binding domains during this catalytic transition. The
movement of coupling helices 2 and 4 appeared to allow helices
4 and 5 and helices 10 and 11 to straighten into much more
ideal α-helical conformations. The straightening of helices 4
and 5 and helices 10 and 11 is hypothesized to occur as a
consequence of the relative twisting of coupling helices 2 and 4.
Coordinated movement of helices 3 and 9 and helices 6 and 12
(which are directly connected to the extracellular ends of
helices 4 and 10 and helices 5 and 11, respectively) together
with the described straightening of helices 4 and 5 and helices
10 and 11 accounted for most of the dramatic opening of the
external face of the DBD as the transition state conformation
was approached. This opening of the extracellular part of the
DBD likely allows dissociation of the bound transport ligand to
the extracellular membrane leaﬂet or the extracellular bulk
matrix.
In this work, transitions between well-established ABC
transporter conformations have been studied using targeted
MD in attempts to assemble a series of conformational changes
that reﬂect structural changes required for catalysis. Over the
course of these simulations, drug and inhibitor binding have
been investigated and the coordinated movements of individual
helices have been correlated with the proposed conformational
changes. The detailed movements described here should
provide ample hypothetical tests for future experimentation.
■ ASSOCIATED CONTENT
* S Supporting Information
Figures S1 and S2 present videos showing the 26 sequential
nonredundant conformational changes of Pgp that were
observed in the targeted molecular dynamics simulations
presented here. Figures S3−S5 show the complex helical
movements observed previously by Loo, Clarke, and co-
workers during ATP hydrolysis for transmembrane helices 1
and 11 and helices 6 and 12. Figure S6 presents video
animations of the helical movements within the drug binding
domains of Pgp that fully open the extracellular face of the
transporter as the catalytic transition state conformation is
approached. Figures S7, S9, and S10 are color versions of
Figures 6−8, respectively, that have color-coded transmem-
brane helices that allow identiﬁcation of speciﬁc substructures
of Pgp should that be desired. Figure S8 shows changes in the
orientation of mutated residues on TM1 and -11 during
simulated catalysis that are known to form disulﬁde cross-links
in an ATP hydrolysis-dependent manner. Table S1 presents the
list of compounds and their relevant characteristics that were
used here in docking studies of the 26 nonredundant Pgp
conformations. Table S2 is a text ﬁle containing a table of
residues of Pgp that come within 3.5 Å of any docked ligand in
any of the 26 nonredundant conformations tested here. This
material is available free of charge via the Internet at http://
pubs.acs.org.
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ABCB1, ATP binding cassette transporter, type B1; DBD, drug
binding domain (the domain of the transporter consisting of
the 12 transmembrane helices and the intracellular extensions
of these helices); DBS, drug binding site(s) (residues of the
transporter found within the drug binding domain that interact
directly with transported ligands); MD, molecular dynamics;
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